Capronor
Capronor Biodegradable Implant
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Subdermal
-
Intended Duration:
- Long-Acting
- Development Stage: Phase II
- Developer(s)/researcher(s): RTI International, NICHD
Details
- API: Levonorgestrel
- Target: Progesterone Receptor, Androgen Receptor
-
Mechanism of Action:
- Ovulation Inhibition
- Cervical Mucus Changes
- Endometrial Changes
- Inactive Materials: Poly-Caprolactone (PCL)
- Regimen: 1 Insertion/12-18 Months
- MPT: Not Potential MPT
Product Status
No indication of further development following identification of concerning side effects in the 1990s
History
During clinical evaluation in the 1990s, the implant was conclusively associated with skin irritation and rash over the insertion site. This, paired with concerns about stability in storage, lack of reliable removability, and a potential long "tail effect" impacting return to fertility after discontinuation halted further development.